Market capitalization | $69.77m |
Enterprise Value | $10.92m |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.38 |
Free Cash Flow (TTM) Free Cash Flow | $-86.81m |
Cash position | $58.85m |
P/E forward | negative |
Short interest | 13.26% |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
5 Analysts have issued a Seres Therapeutics Inc forecast:
5 Analysts have issued a Seres Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -120 -120 |
25%
25%
|
EBIT (Operating Income) EBIT | -126 -126 |
22%
22%
|
Net Profit | 0.14 0.14 |
100%
100%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Eric Shaff |
Employees | 103 |
Founded | 2010 |
Website | www.serestherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.